Alternatives to Quibim

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

Novaflow is an AI data analyst that turns raw biology data into publication-ready figures and methods, no terminal required.

Kim by Oculi Medical reads your lab PDFs and wearable data to deliver daily personalized health guidance.

FDA-cleared echocardiography AI that automates LVEF and screens for cardiac amyloidosis, now backed by a Medicare NTAP.

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

AI patient identification for clinical trials: HealthKey scans your EHR daily and emails your team trial-eligible patients.

AI evidence assembly and quantitative modeling for clinical pharmacology — MBMA databases, Project Optimus dose work, exposure-response

iOS app that turns your daily actions into a biological age and rate-of-aging estimate.

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

PicnicAI turns patient health records into clinical research data and real-world evidence.

Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Physics-based molecular simulation with AI for drug discovery and materials design.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

AI protein engineering that optimizes binding, stability, activity, and expression across wet-lab rounds.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.